This segment focuses on the research and development of novel therapies for severe and life-threatening infectious diseases. The company's research efforts have included preclinical studies and clinical trials aimed at validating the efficacy and safety of Artemisone, a compound with potential activity against human cytomegalovirus (HCMV) and malaria. The segment has pursued orphan drug designation for Artemisone in the treatment of malaria, highlighting its commitment to addressing unmet medical needs in this area. Future opportunities may involve expanding the therapeutic pipeline to include other infectious diseases and exploring strategic partnerships to accelerate drug development and commercialization. Regulatory compliance and clinical validation are critical aspects of this segment's operations.